Shots:
- Hengrui Pharma & Braveheart Bio have entered into an exclusive license agreement for Hengrui’s HRS-1893 to treat cardiovascular diseases
- As per the deal, Braveheart will obtain exclusive global rights (ex-China, Hong Kong, Macao & Taiwan) to develop, manufacture & commercialize HRS-1893 in exchange for $65M upfront (50% in cash + 50% in shares), ~$10M upon tech transfer completion, ~$1.013B in development & commercial milestones, plus royalties on net sales
- HRS-1893, a selective myosin inhibitor, blocks myosin ATPase activity to reduce excessive myocardial contraction, decrease left ventricular hypertrophy, & improve diastolic compliance, with a P-III trial for obstructive hypertrophic cardiomyopathy underway
Ref: Hengrui | Image: Hengrui | Press Release
Related News:- GSK Enters a ~$12.5B Deal with Hengrui Pharma to Develop up to 12 Novel Therapeutics Across Various Indications
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
